‘Glioblastoma broadband power as a longitudinal biomarker for tumor progression’
- Conditions
- Glioblastoma (GBM)
- Registration Number
- NL-OMON27265
- Lead Sponsor
- Amsterdam UMC, location VUmc
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 100
Inclusion Criteria
(1) age > 17 years
(2) histopathologically confirmed GBM
(3) eligible to start the standard treatment of concomitant chemoradiation followed by adjuvant chemotherapy
Exclusion Criteria
(1) psychiatric disease or symptoms at the time of inclusion
(2) other comorbidities of the central nervous system, particularly cerebrovascular accidents, multiple sclerosis, Alzheimer’s disease at the time of inclusion
(3) insufficient mastery of the Dutch language,
(4) inability to communicate adequately.
For undergoing the secondary endpoint of additional MRI measurement, patients are excluded when they have contraindications for MRI, but will still be included for the primary endpoints of MEG/EEG and tumor progression.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method MEG peritumoral BB power,<br>Radiological/Clinical progression
- Secondary Outcome Measures
Name Time Method EEG peritumoral BB power,<br>CEST MRI,<br>rsfMRI, <br>questionnaires